Updates are available Correction dated 2019-07-05
Click to view Correction: https://doi.org/10.1007/s10157-019-01758-x
-
Authors
Tsuruya, Kazuhiko
Shimazaki, Ryutaro
Fukagawa, Masafumi
Akizawa, Tadao
Hayashi, Yoshimitsu
Nakamoto, Hidetomo
Koga, Shoji
Okido, Ichiro
Kubota, Minoru
Koiwa, Fumihiko
Takeda, Masahiro
Hayashi, Terumasa
Hiramatsu, Makoto
Kawanishi, Hideki
Kanai, Hidetoshi
Ito, Sakuya
Tsuruya, Kazuhiko
Mitsuiki, Koji
Ikeda, Hirofumi
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02549417 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
https://doi.org/10.1007/s10157-019-01692-y
- License Information
-
More Information
Article History
Received: 31 July 2018
Accepted: 6 January 2019
First Online: 6 April 2019
Change Date: 5 July 2019
Change Type: Correction
Change Details: The article “Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients.
Compliance with ethical standards
:
: We have read and understood Clinical and Experimental Nephrology’s policy on disclosing conflicts of interest and declare the following interests: KT has received consulting fees from Astellas Pharma Inc.; lecture fees from Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Torii Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd.; and grants from Kyowa Hakko Kirin Co., Ltd. and Chugai Pharmaceutical Co., Ltd. MF has received consulting fees from Kyowa Hakko Kirin Co., Ltd. and Ono Pharmaceutical Co., Ltd.; lecture fees from Kyowa Hakko Kirin Co., Ltd., Bayer Yakuhin, Ltd., Torii Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd.; and grants from Kyowa Hakko Kirin Co., Ltd. and Bayer Yakuhin, Ltd. TA has received consulting fees from Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Fuso Pharmaceutical Industries, Ltd., Japan Tobacco Inc., Ono Pharmaceutical Co., Ltd. and NIPRO Industry, and lecture fees from Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Kissei Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. RS is employed by Kyowa Hakko Kirin Co., Ltd., which funded this research.
: This study was performed in compliance with ethical principles based on the Declaration of Helsinki and the Good Clinical Practice Guidelines. Ethical approval was obtained from the institutional review board of each participating institution.
: All patients provided written informed consent.
